Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
66 participants
INTERVENTIONAL
2007-02-28
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
NCT00784693
Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain
NCT00117481
Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women
NCT00110487
Danazol Treatment in Endometriosis Women Before IVF
NCT01779232
Safety and Efficacy Study of MT-2990 in Women With Endometriosis
NCT03840993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Danazol Once Weekly
semi-solid
2
Danazol Twice Weekly
semi-solid
3
Placebo Once Weekly
semi-solid
4
Placebo Twice Weekly
semi-solid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Danazol Once Weekly
semi-solid
Danazol Twice Weekly
semi-solid
Placebo Once Weekly
semi-solid
Placebo Twice Weekly
semi-solid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Regular cycle length of 21 to 35 days with menstrual bleeding that typically lasts no more than 7 days,
* Has pain associated with endometriosis,
* Has a documented history consistent with endometriosis,
Exclusion Criteria
* Has a history of or has active thrombosis
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lumara Health, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jim Joffrion
Role: STUDY_DIRECTOR
Lumara Health, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chandler, Arizona, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Carmichael, California, United States
San Diego, California, United States
San Diego, California, United States
San Diego, California, United States
Denver, Colorado, United States
Britain, Connecticut, United States
West Hartford, Connecticut, United States
Aventura, Florida, United States
Boynton Beach, Florida, United States
Clearwater, Florida, United States
Hudson, Florida, United States
Tampa, Florida, United States
Alpharetta, Georgia, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
Boise, Idaho, United States
Boise, Idaho, United States
Champaign, Illinois, United States
Baton Rouge, Louisiana, United States
Chesterfield, Missouri, United States
Moorestown, New Jersey, United States
Winston-Salem, North Carolina, United States
Bismarck, North Dakota, United States
Fargo, North Dakota, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Abington, Pennsylvania, United States
West Chester, Pennsylvania, United States
Jackson, Tennessee, United States
Memphis, Tennessee, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
Irving, Texas, United States
Salt Lake City, Utah, United States
Kelowna, British Columbia, Canada
North Vancouver, British Columbia, Canada
Penicton, British Columbia, Canada
Halifax, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Whitby, Ontario, Canada
Windsor, Ontario, Canada
Saskatoon, Saskatchewan, Canada
Moscow, , Russia
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DZ2-201-601-725036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.